共 72 条
[1]
Ting DS(2016)Diabetic retinopathy: global prevalence, major risk factors, screening practices and public health challenges: a review Clin Exp Ophthalmol 44 260-277
[2]
Cheung GC(2014)Intravitreal aflibercept for diabetic macular edema Ophthalmology 121 2247-2254
[3]
Wong TY(2015)Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies Ophthalmology 122 2044-2052
[4]
Korobelnik JF(2018)Impact of baseline diabetic retinopathy severity scale scores on visual outcomes in the VIVID-DME and VISTA-DME studies Br J Ophthalmol 102 954-958
[5]
Do DV(2018)Reply to the letter to the editor: aflibercept in diabetic macular edema refractory to previous bevacizumab: outcomes and predictors of success Graefes Arch Clin Exp Ophthalmol 256 1355-1356
[6]
Schmidt-Erfurth U(2017)Switching to aflibercept in diabetic macular edema not responding to ranibizumab and / or intravitreal dexamethasone implant J Ophthalmol 2017 8035013-223
[7]
Brown DM(2018)One-year outcome of combercept therapy for diabetic macular edema Curr Eye Res 43 218-301
[8]
Schmidt-Erfurth U(2006)Vitreous levels of pigment epithelial-derived factor and vascular endothelial growth factor are related to diabetic macular edema Ophthalmology 113 294-1203
[9]
Do DV(2015)Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema N Engl J Med 372 1193-316
[10]
Staurenghi G(2018)Focusing on the diagnosis and treatment of diabetic macular edema Chin J Ocul Fundus Dis 34 313-732